留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码
x 关闭 永久关闭

应中央军委要求，2022年9月起，《药学实践杂志》将更名为《药学实践与服务》，双月刊，正文96页；2023年1月起，拟出版月刊，正文64页，数据库收录情况与原《药学实践杂志》相同。欢迎作者踊跃投稿！

索拉菲尼与异硫氰酸4-(甲基亚磺酰)丁酯体外协同杀伤肝癌细胞实验研究

何文婷,  巩志荣,  孙治国,  王美平,  高洁,  钟延强,  鲁莹

downloadPDF
文章导航 > 药学实践与服务  > 2015 >  33(2): 138-142
何文婷, 巩志荣, 孙治国, 王美平, 高洁, 钟延强, 鲁莹. 索拉菲尼与异硫氰酸4-(甲基亚磺酰)丁酯体外协同杀伤肝癌细胞实验研究[J]. 药学实践与服务, 2015, 33(2): 138-142. doi: 10.3969/j.issn.1006-0111.2015.02.012
引用本文: 何文婷, 巩志荣, 孙治国, 王美平, 高洁, 钟延强, 鲁莹. 索拉菲尼与异硫氰酸4-(甲基亚磺酰)丁酯体外协同杀伤肝癌细胞实验研究[J]. 药学实践与服务, 2015, 33(2): 138-142. doi: 10.3969/j.issn.1006-0111.2015.02.012
shu
HE Wenting, GONG Zhirong, SUN Zhiguo, WANG Meiping, GAO Jie, ZHONG Yanqiang, LU Ying. Synergic effects of sorafenib combined with sulforaphane against hepatocellular carcinoma cells in vitro[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(2): 138-142. doi: 10.3969/j.issn.1006-0111.2015.02.012
Citation: HE Wenting, GONG Zhirong, SUN Zhiguo, WANG Meiping, GAO Jie, ZHONG Yanqiang, LU Ying. Synergic effects of sorafenib combined with sulforaphane against hepatocellular carcinoma cells in vitro[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(2): 138-142. doi: 10.3969/j.issn.1006-0111.2015.02.012
shu

索拉菲尼与异硫氰酸4-(甲基亚磺酰)丁酯体外协同杀伤肝癌细胞实验研究

doi: 10.3969/j.issn.1006-0111.2015.02.012
  • 1.

    福建中医药大学药学系, 福建 福州 350108

  • 2.

    第二军医大学药学院, 上海 200433

  • 3.

    福建中医药大学药学系, 福建 福州 350108;第二军医大学药学院, 上海 200433

Synergic effects of sorafenib combined with sulforaphane against hepatocellular carcinoma cells in vitro

  • 1.

    Department of Pharmacy, Fujian University of Traditional Chinese Medicine, Fuzhou 350108, China

  • 2.

    Department of Pharmaceutics, School of Pharmacy, Second Military Medical University, Shanghai 200433, China

  • 3.

    Department of Pharmacy, Fujian University of Traditional Chinese Medicine, Fuzhou 350108, China;Department of Pharmaceutics, School of Pharmacy, Second Military Medical University, Shanghai 200433, China

  • 摘要: 目的 探讨索拉菲尼(sorafenib,SO)联合异硫氰酸4-(甲基亚磺酰)丁酯(sulforaphane,SF)杀伤肝癌细胞HepG2的协同比例。 方法 采用CCK-8法探讨SO和SF对HepG2杀伤效果最强的协同比例,利用协同指数(CI)反映协同杀伤效应:CI>1.1为拮抗;0.9结果 CCK-8法显示:SO与SF在摩尔比为1:1、1:10、1:20时,为拮抗作用(CI>1.1);在10:1时,为相加作用(0.9P<0.01),早期和晚期凋亡率(21.71±6.06)%显著高于拮抗比例1:1的凋亡率(6.64±0.31)%(P<0.01)。 结论 SO和SF摩尔比为5:1时能达到协同杀伤HepG2肝癌细胞的效果。
    Abstract: Objective To investigate the synergic ratio of sorafenib (SO) and sulforaphane (SF) against the hepatocellular carcinoma cell line HepG2 in vitro. Methods The synergic effect of SO combined with SF against HepG2 cells was determined by the CCK8 assay (the synergic effect was determined by combination index (CI) value: CI>1.1, antagonistic; 0.9Results The CCK-8 assay showed that SO combined with SF at the molar rate of 1:1,1:10 and 1:20 exhibited strong antagonism (CI>1.1), whereas 20:1,5:1 and 1:5 ratio resulted in synergistic activity (CI<0.9). Furthermore, 10:1 ratio acted as an additive effective (0.9P<0.01). The early and late apoptosis rate of HepG2 cells (21.71±6.06) of the group treated with SO combined with SF at 5:1 synergistic ratio was significantly higher than that of the group treated with SO combined with SF at 1:1 antagonistic ratio(6.64±0.311)(P<0.01). Conclusion SO combined with SF at the molar rate of 5:1 can synergistically inhibit the growth of hepatocellular carcinoma cell line HepG2 in vitro.
  • [1] Wilhelm SM,Adnane L,Newell P,et al.Preclinical over view of sorafenib,a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling[J].Mol Cancer Ther,2008,7(10):3129 3140.
    [2] Paez-Ribes M, Allen E, Hudock J, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis[J].Cancer Cell,2009,15(3):220 231.
    [3] Ebos JM, Lee CR, Cruz-Munoz W, et al. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis[J]. Cancer Cell,2009,15(3):232 239.
    [4] Rausch V, Lui L, Kallifatidis G, et al. Synergistic activity of sorafenib and sulforaphane abolishes pancreatic cancer stem cell characteristics[J]. Cancer Res,2010,70(12):5004-5013.
    [5] Choi S, Lew KL, Xiao H, et al. D,L-Sulforaphane-induced cell death in human prostate cancer cells is regulated by inhibitor of apoptosis family proteins and Apaf-1[J]. Carcinogenesis,2007,28(1):151 162.
    [6] Xu C, Shen G, Chen C, et al. Suppression of NF-kappaB and NF-kappaB-regulated gene expression by sulforaphane and PEITC through IkappaBalpha, IKK pathway in human prostate cancer PC-3 cells[J]. Oncogene,2005,24(28):4486-4495.
    [7] Jeong WS, Kim IW, Hu R,et al. Modulatory properties of various natural chemopreventive agents on the activation of NF-kappaB signaling pathway[J]. Pharm Res,2004,21(4):661 670.
    [8] Tardi P, Johnstone S, Harasym N,et al. In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy[J].Leuk Res,2009,33(1):129-139.
    [9] Kupsch P, Henning B, Passarge K, et al. Results of a phase Ⅰ trial of sorafenib (BAY 43-9006) in combination with oxaliplatin in patients with refractory solid tumors, including colorectal cancer[J]. Clin Colorectal Cancer, 2005,5(3):188-196.
    [10] Lee J, Kang WK, Kwon JM, et al.Phase Ⅱ trial of irinotecan plus oxaliplatin and 5-fluorouracil/leucovorin in patients with untreated metastatic gastric adenocarcinoma.[J].Ann Oncol,2007,18(1):88-92.
    [11] Richly H, Henning B, Kupsch P, et al. Results of a phase Ⅰ trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors[J]. Ann Oncol,2006,17(5):866 873.
    [12] Jonge MJA, Dumez H,Kitzen JEM, et al. Phase Ⅰ safety and pharmacokinetic study of SU-014813 in combination with docetaxel in patients with advanced solid tumours[J].Eur J Cancer,2011,47(9):1328-1335.
    [13] Flaherty KT, Lee SJ, Zhao F, et al.Phase Ⅲ trial of carboplatin and paclitacel with or without sorafenib in metastatic melanoma[J].J Clin Oncol,2013,31(3):373-379.
    [14] Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis[J].Cancer Res,2004,64(19):7099-7109.
    [15] Carlomagno F, Anaganti S, Guida T, et al. BAY 43-9006 inhibition of oncogenic RET mutants[J]. J Natl Cancer Inst, 2006,98(5):326-334.
    [16] Clarke JD, Dashwood RH, Ho E. Multi-targeted prevention of cancer by sulforaphane[J].Cancer Lett, 2008,269(2):291-304.
    [17] Zhang Y, Tang L. Discovery and development of sulforaphane as a cancer chemopreventive phytochemical[J].Acta Pharmacol Sin, 2007,28(9):1343-1354.
    [18] Pavillard V, Kherfellah D, Richard S, et al. Effects of the combination of camptothecin and doxorubicin or etoposide on rat glioma cells and camptothecin-resistant variants[J].Br J Cancer, 2001,85(7):1077-1083.
  • [1] 陈炳辰, 佟达丰, 万苗, 闫飞虎, 姚建忠.  UPLC-MS/MS法测定小鼠血浆中紫杉醇脂肪酸酯前药及其药代动力学研究 . 药学实践与服务, 2024, 42(8): 341-345. doi: 10.12206/j.issn.2097-2024.202404082
    [2] 郭灵怡, 刘艳超, 高路, 刘瑞瑶, 吕权真, 俞媛.  醋酸卡泊芬净单硬脂酸甘油酯纳米粒抗白色念珠菌感染的增效作用研究 . 药学实践与服务, 2024, 42(): 1-8. doi: 10.12206/j.issn.2097-2024.202310043
    [3] 陈炳辰, 王思真, 郭贝贝, 杨峰.  紫杉醇棕榈酸酯的合成及其脂质体的制备与处方研究 . 药学实践与服务, 2024, 42(9): 379-384, 410. doi: 10.12206/j.issn.2097-2024.202404062
    [4] 徐璐璐, 刘爱军.  丹参白术方“异病同治”冠心病、血管性痴呆、特发性膜性肾病的网络药理学作用机制研究 . 药学实践与服务, 2024, 42(12): 1-8. doi: 10.12206/j.issn.2097-2024.202312027
    [5] 崔亚玲, 吴琼, 马良煜, 胡北, 姚东, 许子华.  肝素钠肌醇烟酸酯乳膏中肌醇烟酸酯皮肤药动学研究 . 药学实践与服务, 2024, 42(): 1-5. doi: 10.12206/j.issn.2097-2024.202404006
    [6] 刘汝雄, 杨万镇, 涂杰, 盛春泉.  铁死亡调控蛋白GPX4的小分子抑制剂研究进展 . 药学实践与服务, 2024, 42(9): 375-378. doi: 10.12206/j.issn.2097-2024.202312075
    [7] 李丹, 戴贤春, 王芳珍, 陈奕含, 杨萍, 刘继勇.  HPLC-MS/MS测定当归六黄汤中4种不同成分的含量 . 药学实践与服务, 2024, 42(6): 248-252, 266. doi: 10.12206/j.issn.2097-2024.202305007
    [8] 毛智毅, 王筱燕, 陈晓颖, 汤逸斐.  度拉糖肽联合二甲双胍对肥胖型2型糖尿病患者机体代谢、体脂成分及血清脂肪因子的影响 . 药学实践与服务, 2024, 42(7): 305-309. doi: 10.12206/j.issn.2097-2024.202305032
    [9] 凯丽比努尔·奥布力艾散, 李倩, 谢志, 贾文彦, 尹东锋.  星点设计-效应面法优化仑伐替尼混合胶束的制备工艺 . 药学实践与服务, 2024, 42(11): 495-502. doi: 10.12206/j.issn.2097-2024.202403019
    [10] 姚小静, 计佩影, 陆峰, 施国荣, 傅翔.  表面增强拉曼光谱法快速测定尿液中曲马多的研究 . 药学实践与服务, 2024, 42(): 1-5. doi: 10.12206/j.issn.2097-2024.202401072
    [11] 崔晓林, 付晓菲, 杜艳红, 刘娟, 朱茜, 刘子祺.  临床药师参与吉瑞替尼致QTc间期延长的病例分析 . 药学实践与服务, 2024, 42(6): 263-266. doi: 10.12206/j.issn.2097-2024.202309050
    [12] 杨媛媛, 安晓强, 许佳捷, 江键, 梁媛媛.  正极性驻极体联合5-氟尿嘧啶对瘢痕成纤维细胞生长抑制的协同作用 . 药学实践与服务, 2024, 42(6): 244-247. doi: 10.12206/j.issn.2097-2024.202310027
  • 加载中
WeChat 点击查看大图
计量
  • 文章访问数:  3203
  • HTML全文浏览量:  190
  • PDF下载量:  418
  • 被引次数: 0
出版历程
  • 收稿日期:  2014-09-28
  • 修回日期:  2014-12-26

索拉菲尼与异硫氰酸4-(甲基亚磺酰)丁酯体外协同杀伤肝癌细胞实验研究

doi: 10.3969/j.issn.1006-0111.2015.02.012
  • 1. 福建中医药大学药学系, 福建 福州 350108
  • 2. 第二军医大学药学院, 上海 200433
  • 3. 福建中医药大学药学系, 福建 福州 350108;第二军医大学药学院, 上海 200433
  • 收稿日期: 2014-09-28
  • 修回日期: 2014-12-26

摘要: 目的 探讨索拉菲尼(sorafenib,SO)联合异硫氰酸4-(甲基亚磺酰)丁酯(sulforaphane,SF)杀伤肝癌细胞HepG2的协同比例。 方法 采用CCK-8法探讨SO和SF对HepG2杀伤效果最强的协同比例,利用协同指数(CI)反映协同杀伤效应:CI>1.1为拮抗;0.9结果 CCK-8法显示:SO与SF在摩尔比为1:1、1:10、1:20时,为拮抗作用(CI>1.1);在10:1时,为相加作用(0.9P<0.01),早期和晚期凋亡率(21.71±6.06)%显著高于拮抗比例1:1的凋亡率(6.64±0.31)%(P<0.01)。 结论 SO和SF摩尔比为5:1时能达到协同杀伤HepG2肝癌细胞的效果。

English Abstract

何文婷, 巩志荣, 孙治国, 王美平, 高洁, 钟延强, 鲁莹. 索拉菲尼与异硫氰酸4-(甲基亚磺酰)丁酯体外协同杀伤肝癌细胞实验研究[J]. 药学实践与服务, 2015, 33(2): 138-142. doi: 10.3969/j.issn.1006-0111.2015.02.012
引用本文: 何文婷, 巩志荣, 孙治国, 王美平, 高洁, 钟延强, 鲁莹. 索拉菲尼与异硫氰酸4-(甲基亚磺酰)丁酯体外协同杀伤肝癌细胞实验研究[J]. 药学实践与服务, 2015, 33(2): 138-142. doi: 10.3969/j.issn.1006-0111.2015.02.012
shu
HE Wenting, GONG Zhirong, SUN Zhiguo, WANG Meiping, GAO Jie, ZHONG Yanqiang, LU Ying. Synergic effects of sorafenib combined with sulforaphane against hepatocellular carcinoma cells in vitro[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(2): 138-142. doi: 10.3969/j.issn.1006-0111.2015.02.012
Citation: HE Wenting, GONG Zhirong, SUN Zhiguo, WANG Meiping, GAO Jie, ZHONG Yanqiang, LU Ying. Synergic effects of sorafenib combined with sulforaphane against hepatocellular carcinoma cells in vitro[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(2): 138-142. doi: 10.3969/j.issn.1006-0111.2015.02.012
shu

    全文HTML

参考文献 (18)

目录

    /

    返回文章
    返回

    版权所有：《药学实践与服务》编辑委员会

    主管、主办: 中国人民解放军海军军医大学地址: 上海市杨浦区国和路325号邮政编码: 200433

    电话: （021）81871324,81871397 E-mail: [email protected]

    网站备案号 沪ICP备05003363号-1

    本系统由 北京仁和汇智信息技术有限公司 开发    百度统计